Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Race Oncology Ltd. ( (AU:RAC) ) has provided an update.
Racura Oncology has announced the cessation of 500,880 options (ASX code RACAAD), which were due to expire on June 30, 2029, at an exercise price of $1.67. These options lapsed because the conditions attached to the rights were not met or could no longer be satisfied, resulting in a reduction of potential future dilution and a clearer picture of the company’s issued capital structure for investors.
The announcement formalises the removal of these contingent securities from Racura’s capital base as of April 23, 2026. This adjustment may marginally tighten the company’s equity profile and can influence how stakeholders assess outstanding incentives and potential future share issuance under the company’s long-term capital and remuneration plans.
More about Race Oncology Ltd.
Racura Oncology Ltd is an ASX-listed biotechnology company focused on developing oncology treatments. The company operates in the cancer therapeutics sector, using capital market instruments such as options to support its financing and incentive structures within the Australian securities market.
Average Trading Volume: 209,204
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$584.7M
See more insights into RAC stock on TipRanks’ Stock Analysis page.